IDRA
Closed
Idera Pharmaceuticals Inc
4.99
-2.24 (-31.00%)
Last Update: 15 Feb 2023 17:30:00
Yesterday: 7.225
Day's Range: 4.73 - 5.04
Send
sign up or login to leave a comment!
When Written:
4.99
Idera Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that is focused on developing novel nucleic acid-based therapies for the treatment of cancer and rare diseases. The company's proprietary technology platform is designed to activate the immune system to fight against cancer cells and other diseases.
Idera's lead product candidate, IMO-2125, is a toll-like receptor (TLR) 9 agonist that is being developed for the treatment of metastatic melanoma and other solid tumors. The company is also developing other TLR agonists, including IMO-8400 for the treatment of rare genetic disorders and autoimmune diseases.
Idera is headquartered in Exton, Pennsylvania, and was founded in 1989. The company is publicly traded on the NASDAQ under the ticker symbol IDRA.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Idera's lead product candidate, IMO-2125, is a toll-like receptor (TLR) 9 agonist that is being developed for the treatment of metastatic melanoma and other solid tumors. The company is also developing other TLR agonists, including IMO-8400 for the treatment of rare genetic disorders and autoimmune diseases.
Idera is headquartered in Exton, Pennsylvania, and was founded in 1989. The company is publicly traded on the NASDAQ under the ticker symbol IDRA.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








